Researchers at NYU Langone Health and its Perlmutter Cancer Center have made a significant discovery regarding skin cancer. They found that blood tests could potentially predict if skin cancer might return. Melanoma, although not the most common skin cancer, poses a greater danger due to its tendency to spread rapidly if not caught early.
The study, highlighted in The Lancet Oncology journal, focused on circulating tumor DNA (ctDNA) present in the blood of cancer patients. Astonishingly, about 80% of stage 3 melanoma patients with detectable ctDNA levels saw their cancer return. Stage 3 melanoma is particularly aggressive because it spreads to the lymph nodes.
Traditional methods like X-rays and CT scans become less effective once lymph nodes are surgically removed. This challenge has driven the interest in innovative ways to monitor cancer. Melanoma’s swift spread makes it a critical focus, as noted by experts, including those from Fox News.
Lead author Mahrukh Syeda stated, “Our findings suggest that circulating tumor DNA tests could help oncologists identify which melanoma patients are most likely to respond well to therapy.” Early detection using ctDNA analysis might save lives since this cancer is tough to treat once it spreads.
The research included nearly 600 participants from an earlier clinical trial. Blood samples were used to investigate the relationship between ctDNA levels and cancer recurrence. Factors like age, sex, and therapy type were considered during the analysis.
Almost all patients with detectable ctDNA within a year post-treatment experienced melanoma’s return. The ctDNA method zeroes in on common mutations within melanoma cells’ genetic code. The study revealed that assessing ctDNA levels was as predictive, if not more so, than other tumor-based tests.
David Polsky, a senior author and dermatologist, remarked, “Unlike standard, tissue-based analyses of tumor cells, circulating tumor DNA tests provide a clear, direct measure of the disease itself.” Despite the promising results, some patients experienced cancer recurrence even when ctDNA tests were negative.
Researchers aim to enhance test sensitivity to minimize such instances. Dr. Joshua Strauss, a hematologist and oncologist, praised the research, emphasizing the growing ability of technologies to detect tumor DNA in the blood. This advancement is seen as a crucial step in cancer management.
Persistent circulating tumor DNA after surgery is a troubling indicator of potential early recurrence, Strauss mentioned. The next goal is to leverage this information not only for prognostic purposes but also to guide treatment decisions.
